Cutaneous fibrous histiocytoma

Summary

Cutaneous fibrous histiocytoma (MONDO:0006717) is a disease and 2 clinical trials. Top therapeutic interventions include pazopanib and ifosfamide. A subtype of dermis tumor — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	cutaneous fibrous histiocytoma
Mondo ID	MONDO:0006717
EFO	EFO:1000885
DOID	DOID:4418
NCIT	C6801
SNOMED CT	448015002
UMLS	C0002991
MedGen	1930
GARD	0024461
Is cancer (heuristic)	no

Also known as: benign cutaneous fibrous histiocytoma · benign fibrous cutaneous histiocytoma · benign fibrous histiocytoma of skin · benign fibrous histiocytoma of the skin · benign skin fibrous histiocytoma · cutaneous fibrous histiocytoma · dermatofibroma · dermatofibroma, no ICD-O subtype · dermatofibroma, no ICD-O subtype (morphologic abnormality) · DF · fibrohistiocytic neoplasm · fibrohistiocytic tumour · fibrous histiocytoma of skin · fibrous histiocytoma of the skin · sclerosing angioma (morphologic abnormality)

Disease family

This is a subtype of dermis tumor. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › skin neoplasm › dermis tumor › cutaneous fibrous histiocytoma

Related subtypes (7): cutaneous granular cell tumor, skin glomus tumor, leiomyoma cutis, malignant dermis tumor, juvenile hyaline fibromatosis, cutaneous mastocytosis, angioma serpiginosum

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2/PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02180867	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
NCT00540566	Not specified	COMPLETED	Optical Biopsy of Human Skin in Conjunction With Laser Treatment

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PAZOPANIB	4	3
IFOSFAMIDE	4	1
CHEMBL4068768	0	1
CHEMBL4171277	0	1